Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
41116158
NACRES:
NA.54
Storage temp.:
2-8°C
Shipped in:
wet ice
usage
sufficient for ≤1,000 tests
manufacturer/tradename
Roche
technique(s)
ELISA: suitable
detection method
chemiluminescent
shipped in
wet ice
storage temp.
2-8°C
General description
Chemiluminescent immunoassay for the quantification of cell proliferation, based on the measurement of BrdU incorporation during DNA synthesis: a nonradioactive alternative to the [3H]-thymidine incorporation assay.
Application
Cell Proliferation ELISA, BrdU (chemiluminescent) has been used:
- for bromodeoxyuridine (BrdU) proliferation assay in ReN and primary astrocytes
- to test the effect on imatinib on the proliferation of neuroblastoma cells using BrdU incorporation assay
- to check the effect of palbociclib on cell cycle inhibition using BrdU incorporation in pancreatic patient-derived primary cell lines
The Cell Proliferation ELISA, BrdU (chemiluminescent) belongs to the second, improved generation of kits for measuring DNA synthesis. It is a precise, fast, and simple nonradioactive alternative to quantitate cell proliferation based on the measurement of BrdU incorporation during DNA synthesis in replicating (cycling) cells. Thus, the Cell Proliferation ELISA can be used in many different in vitro cell systems. For example:
- Detection and quantification of cell proliferation induced by growth factors and cytokines
- Determination of the inhibitory or stimulatory effects of various compounds on cell proliferation in environmental and biomedical research, and in the food, cosmetic, and pharmaceutical industries
- Measurement of the immunoreactivity of lymphocytes, stimulated by mitogens or antigens
- Analysis of the chemosensitivity of tumor cells to different cytostatic drugs in medical research
Biochem/physiol Actions
The antibody conjugate reacts with the thymidine analogue 5-bromo-2′-deoxyuridine (BrdU) and with BrdU incorporated into DNA. For binding to BrdU incorporated into the DNA, the BrdU-labeled DNA has to be denatured. The antibody does not cross-react with any endogenous cellular components such as thymidine, uridine, or DNA.
Packaging
1 kit containing 7 components.
Other Notes
- BrdU Labeling Reagent, 1,000x conc
- FixDenat
- Anti-BrdU-POD 4. Antibody Dilution Solution
- Washing Buffer PBS, 10x conc.
- Substrate Component A
- Substrate Component B
For life science research only. Not for use in diagnostic procedures.
Kit Components Only
Product No.
Description
- BrdU Labeling Reagent
- FixDenat ready-to-use
- Anti-BrdU-peroxidase antibody
- Antibody Dilution Solution ready-to-use
- ready-to-use 10x concentrated
- Substrate Component A
- Substrate Component B
signalword
Danger
hcodes
Hazard Classifications
Eye Irrit. 2 - Flam. Liq. 2 - Muta. 1B - Skin Sens. 1
Storage Class
3 - Flammable liquids
wgk
WGK 1
Regulatory Information
低风险生物材料
常规特殊物品
危险化学品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
Cell based assays for cell proliferation (BrdU, MTT, WST1), cell viability and cytotoxicity experiments for applications in cancer, neuroscience and stem cell research.
Cell cycle regulates vital processes like DNA repair, cancer prevention. Four stages: G1, S, G2, M. NTPs don't permeate membranes.
基于细胞的细胞增殖(BrdU、MTT、WST1)、细胞活力和细胞毒性实验,可应用于癌症、神经科学和干细胞研究。
Related Content
Xiao-Feng Wang et al.
Molecular medicine reports, 12(4), 5917-5923 (2015-08-25)
Epirubicin, an anthracycline derivative, is one of the main line treatments for brain tumors. The aim of the present study was to verify that epirubicin alters the growth and morphological characteristics of U‑87 glioma cells. In the present study, the
Valerio Ciccone et al.
Oncotarget, 9(17), 13353-13365 (2018-03-24)
Nitric oxide (NO) exerts conflicting effect on tumor growth and progression, depending on its concentration. We aimed to characterize the anti-cancer activity of a new NO donor, Ni(SalPipNONO) belonging to the class of metal-nonoates, in epithelial derived tumor cells, finally
Juliann E Kosovec et al.
Oncotarget, 8(59), 100421-100432 (2017-12-17)
Esophageal adenocarcinoma (EAC) is a deadly disease with limited therapeutic options. In the present study, we determined the preclinical efficacy of CDK4/6 inhibitor abemaciclib for treatment of EAC. In vitro, apoptosis, proliferation, and pathway regulation were evaluated in OE19, OE33
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 11669915001 | 04061838250933 |


